U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06824883) titled 'Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma' on Feb. 08.
Brief Summary: This is a single-arm phase 2 study designed to evaluate the safety and efficacy of sintilimab, pegaspargase combined with gemcitabine and oxaliplatin (P-P-GEMOX regimen) as first-line treatment for patients with ENKTL. The primary endpoint is the complete response rate (CRR) in the intention-to-treat population.The secondary endpoints were overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events.
Study Start Date: May 20, 2024
Study Type: INTERVENTIONAL
Condition:
Extranodal N...